SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

NCT01744236 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Liraglutide
DRUG: Sitagliptin
DRUG: Exenatide
DRUG: Liraglutide placebo
DRUG: Sitagliptin placebo
DRUG: Exenatide placebo
DRUG: L-NMMA

Sponsor

Amsterdam UMC, location VUmc

Collaborators

[object Object]